134 related articles for article (PubMed ID: 24366498)
21. Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer.
Wang L; Lin YL; Li B; Wang YZ; Li WP; Ma JG
J Int Med Res; 2014 Oct; 42(5):1085-92. PubMed ID: 25015764
[TBL] [Abstract][Full Text] [Related]
22. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.
Kawamoto K; Enokida H; Gotanda T; Kubo H; Nishiyama K; Kawahara M; Nakagawa M
Biochem Biophys Res Commun; 2006 Jan; 339(3):790-6. PubMed ID: 16316628
[TBL] [Abstract][Full Text] [Related]
23. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor.
Kim EJ; Kim YJ; Jeong P; Ha YS; Bae SC; Kim WJ
J Urol; 2008 Sep; 180(3):1141-5. PubMed ID: 18639281
[TBL] [Abstract][Full Text] [Related]
24. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer.
Ellinger J; El Kassem N; Heukamp LC; Matthews S; Cubukluoz F; Kahl P; Perabo FG; Müller SC; von Ruecker A; Bastian PJ
J Urol; 2008 Jan; 179(1):346-52. PubMed ID: 18006010
[TBL] [Abstract][Full Text] [Related]
25. Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer.
Malekzadeh K; Sobti RC; Nikbakht M; Shekari M; Hosseini SA; Tamandani DK; Singh SK
Cancer Invest; 2009 Jan; 27(1):70-80. PubMed ID: 19160091
[TBL] [Abstract][Full Text] [Related]
26. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.
Jarmalaite S; Jankevicius F; Kurgonaite K; Suziedelis K; Mutanen P; Husgafvel-Pursiainen K
Oncology; 2008; 75(3-4):145-51. PubMed ID: 18824877
[TBL] [Abstract][Full Text] [Related]
27. Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer.
Scher MB; Elbaum MB; Mogilevkin Y; Hilbert DW; Mydlo JH; Sidi AA; Adelson ME; Mordechai E; Trama JP
J Urol; 2012 Dec; 188(6):2101-7. PubMed ID: 23083854
[TBL] [Abstract][Full Text] [Related]
28. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features.
Maruyama R; Toyooka S; Toyooka KO; Harada K; Virmani AK; Zöchbauer-Müller S; Farinas AJ; Vakar-Lopez F; Minna JD; Sagalowsky A; Czerniak B; Gazdar AF
Cancer Res; 2001 Dec; 61(24):8659-63. PubMed ID: 11751381
[TBL] [Abstract][Full Text] [Related]
29. Methylated DNA and total DNA in serum detected by one-step methylation-specific PCR is predictive of poor prognosis for breast cancer patients.
Fujita N; Nakayama T; Yamamoto N; Kim SJ; Shimazu K; Shimomura A; Maruyama N; Morimoto K; Tamaki Y; Noguchi S
Oncology; 2012; 83(5):273-82. PubMed ID: 22964822
[TBL] [Abstract][Full Text] [Related]
30. Methylation of a novel panel of tumor suppressor genes in urine moves forward noninvasive diagnosis and prognosis of bladder cancer: a 2-center prospective study.
García-Baquero R; Puerta P; Beltran M; Alvarez M; Sacristan R; Alvarez-Ossorio JL; Sánchez-Carbayo M
J Urol; 2013 Aug; 190(2):723-30. PubMed ID: 23485510
[TBL] [Abstract][Full Text] [Related]
31. Frequent silencing of protocadherin 17, a candidate tumour suppressor for esophageal squamous cell carcinoma.
Haruki S; Imoto I; Kozaki K; Matsui T; Kawachi H; Komatsu S; Muramatsu T; Shimada Y; Kawano T; Inazawa J
Carcinogenesis; 2010 Jun; 31(6):1027-36. PubMed ID: 20200074
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic inactivation of ITIH5 promotes bladder cancer progression and predicts early relapse of pT1 high-grade urothelial tumours.
Rose M; Gaisa NT; Antony P; Fiedler D; Heidenreich A; Otto W; Denzinger S; Bertz S; Hartmann A; Karl A; Knüchel R; Dahl E
Carcinogenesis; 2014 Mar; 35(3):727-36. PubMed ID: 24265292
[TBL] [Abstract][Full Text] [Related]
33. Comparative promoter methylation analysis of p53 target genes in urogenital cancers.
Christoph F; Hinz S; Weikert S; Kempkensteffen C; Schostak M; Miller K; Schrader M
Urol Int; 2008; 80(4):398-404. PubMed ID: 18587251
[TBL] [Abstract][Full Text] [Related]
34. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma.
Friedrich MG; Chandrasoma S; Siegmund KD; Weisenberger DJ; Cheng JC; Toma MI; Huland H; Jones PA; Liang G
Eur J Cancer; 2005 Nov; 41(17):2769-78. PubMed ID: 16242928
[TBL] [Abstract][Full Text] [Related]
35. Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine.
Lin HH; Ke HL; Huang SP; Wu WJ; Chen YK; Chang LL
Urol Oncol; 2010; 28(6):597-602. PubMed ID: 19181545
[TBL] [Abstract][Full Text] [Related]
36. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ.
Horikawa Y; Sugano K; Shigyo M; Yamamoto H; Nakazono M; Fujimoto H; Kanai Y; Hirohashi S; Kakizoe T; Habuchi T; Kato T
J Urol; 2003 Apr; 169(4):1541-5. PubMed ID: 12629411
[TBL] [Abstract][Full Text] [Related]
37. MSH2 promoter hypermethylation in circulating tumor DNA is a valuable predictor of disease-free survival for patients with esophageal squamous cell carcinoma.
Ling ZQ; Zhao Q; Zhou SL; Mao WM
Eur J Surg Oncol; 2012 Apr; 38(4):326-32. PubMed ID: 22265839
[TBL] [Abstract][Full Text] [Related]
38. Frequent promoter methylation of M-cadherin in hepatocellular carcinoma is associated with poor prognosis.
Yamada S; Nomoto S; Fujii T; Takeda S; Kanazumi N; Sugimoto H; Nakao A
Anticancer Res; 2007; 27(4B):2269-74. PubMed ID: 17695513
[TBL] [Abstract][Full Text] [Related]
39. HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria.
Wu Y; Jiang G; Zhang N; Liu S; Lin X; Perschon C; Zheng SL; Ding Q; Wang X; Na R; Sun J; Xu J
Eur Urol Focus; 2020 Mar; 6(2):284-291. PubMed ID: 30309818
[TBL] [Abstract][Full Text] [Related]
40. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.
Dhawan D; Hamdy FC; Rehman I; Patterson J; Cross SS; Feeley KM; Stephenson Y; Meuth M; Catto JW
J Pathol; 2006 Jul; 209(3):336-43. PubMed ID: 16639696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
